RE:IP Rights and how it relates to Holdings vs Therapeutics Those were my thoughts too, Calgary. Merging is essential only if there is a sale, not necessarily licensing. Licensing is adequately provided for under the original AHI-Antibe agreement.
I would argue that there is additional existing IP in the form of propriatary data developed by Antibe during its many trials, lab tests, etc. There will be additional IP coming with the development of new new molecules, new patents (American chemist), etc. Antibe would be the owner of this.
So what proportion of the royalties associated with the new molecules should go to AHI with its decade old patents? Don't know...but it is worth sorting out. Hence, one of the reasons for consolidating the two companies.
AHI is not going to give up ownership of its IP without compensation. We have to rely on the Board to determine it is in the company's best interests to proceed, and if so, when, and at what price.